Advertisement
Singapore markets closed
  • Straits Times Index

    3,290.04
    +17.32 (+0.53%)
     
  • S&P 500

    5,070.55
    +59.95 (+1.20%)
     
  • Dow

    38,503.69
    +263.71 (+0.69%)
     
  • Nasdaq

    15,696.64
    +245.33 (+1.59%)
     
  • Bitcoin USD

    66,469.17
    +243.59 (+0.37%)
     
  • CMC Crypto 200

    1,432.37
    +8.27 (+0.58%)
     
  • FTSE 100

    8,076.73
    +31.92 (+0.40%)
     
  • Gold

    2,328.00
    -14.10 (-0.60%)
     
  • Crude Oil

    82.87
    -0.49 (-0.59%)
     
  • 10-Yr Bond

    4.5980
    -0.0250 (-0.54%)
     
  • Nikkei

    38,460.08
    +907.92 (+2.42%)
     
  • Hang Seng

    17,201.27
    +372.34 (+2.21%)
     
  • FTSE Bursa Malaysia

    1,571.48
    +9.84 (+0.63%)
     
  • Jakarta Composite Index

    7,174.53
    +63.72 (+0.90%)
     
  • PSE Index

    6,572.75
    +65.95 (+1.01%)
     

Depomed versus Peers in March 2018: Analyst Ratings

Depomed versus Peers in March 2018: Analyst Ratings

Depomed (DEPO) is a specialty pharmaceutical company with a focus on pain and CNS (central nervous system) conditions. In March 2018, two of the seven analysts covering Depomed have given the stock a “buy” rating. By comparison, of the 22 analysts covering Merck (MRK) in March 2018, six analysts have given the stock a “strong buy” rating, and seven analysts have given it a “buy” rating, while nine analysts have given it a “hold” rating.